

ASX Announcement

27 November

Antisense Therapeutics to present at "Australian Equities Day"

Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY | FSE: AWY) is pleased to announce its participation in the "Australian Equities Day" Webinar Presentation hosted by Spark Plus (ANP's Asia focused representative) to be held on Wednesday 2nd December 2020 at 10.45pm AWST / 1.45pm AEDT.

To access further details of the event and to register, please follow the link below:

https://us02web.zoom.us/webinar/register/6416057774774/WN_xeIvUNBIRtKgmJp0h5Ea9Q

Following on from the recent oversubscribed capital raising, Mark Diamond, Chief Executive Officer of Antisense Therapeutics will present an update on the Company, the upcoming milestones and value creation catalysts as the ANP progresses towards initiation of its Phase IIb clinical trial in boys with Duchenne muscular dystrophy in Europe.

This announcement has been authorised for release by the Managing Director.

For more information please contact:

Antisense Therapeutics

Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.